We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TPVG:NYSETriplePoint Venture Growth BDC Corp. Analysis

Data as of 2026-05-05 - not real-time

$5.52

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

TriplePoint Venture Growth BDC trades at a trailing P/E of roughly 4.5 versus an industry average near 17.4, and its price‑to‑book sits under 0.7, signaling a materially undervalued position. The stock yields an eye‑popping 18% dividend, but a payout ratio close to 90% raises questions about sustainability, especially given a negative revenue growth of about -12.7% and a debt‑to‑equity ratio exceeding 130%. Technicals are modestly supportive: the price of $5.52 sits above the 20‑day SMA, the MACD histogram is positive with a bullish signal, and the RSI is neutral at ~57, while the beta of ~0.77 and a 30‑day volatility above 42% indicate a fairly volatile but not overly market‑correlated profile. Recent news confirming an investment‑grade rating and a stable outlook adds a layer of credit confidence despite the high leverage.
Given the deep discount to peers, the strong operating margin of nearly 60%, and the current dividend payout pressure, the stock appears positioned for a potential bounce if earnings stabilize, yet the combination of high debt, declining top‑line, and dividend sustainability concerns tempers enthusiasm. The neutral price trend and decreasing volume suggest limited short‑term momentum, reinforcing a cautious “hold” stance across horizons while monitoring cash‑flow and credit metrics.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish MACD and price above short‑term SMA
  • Undervalued valuation multiples
  • Dividend payout sustainability concerns

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • High leverage and debt‑to‑equity ratio
  • Negative revenue growth trend
  • Investment‑grade rating providing credit cushion

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Potential credit risk from portfolio companies
  • Unsustainable dividend policy
  • Attractive valuation if earnings stabilize

Key Metrics & Analysis

Financial Health

Revenue Growth-12.70%
Profit Margin54.46%
P/E Ratio4.5
ROE14.07%
ROA5.36%
Debt/Equity132.65
P/B Ratio0.6
Op. Cash Flow$-57033000
Free Cash Flow$32.4M
Industry P/E17.4

Technical Analysis

TrendNeutral
RSI57.0
Support$4.93
Resistance$5.70
MA 20$5.33
MA 50$5.20
MA 200$5.96
MACDBullish
VolumeDecreasing
Fear & Greed Index90.59

Valuation

Target Price$5.85
Upside/Downside6.07%
GradeUndervalued
TypeValue
Dividend Yield18.00%

Risk Assessment

Beta0.77
Volatility42.52%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.